Profile data is unavailable for this security.
About the company
Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
- Revenue in EUR (TTM)1.55m
- Net income in EUR-44.24m
- Incorporated2009
- Employees30.00
- LocationPoxel SAImm Le Sunway259/261 Avenue Jean JauresLYON 69007FranceFRA
- Phone+33 437372010
- Fax+33 437708815
- Websitehttps://www.poxelpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plant Advanced Technologies PAT SA | 1.68m | 79.16k | 17.61m | 27.00 | 219.46 | 2.06 | 30.38 | 10.47 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | 62,278.52 | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Phaxiam Therapeutics SA | 1.33m | -23.49m | 19.16m | 51.00 | -- | 0.4927 | -- | 14.45 | -5.14 | -5.14 | 0.2901 | 3.90 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 20.65m | 22.00 | -- | 5.12 | -- | 19.26 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Valbiotis SA | 4.73m | -7.37m | 21.26m | 52.00 | -- | 1.08 | -- | 4.49 | -0.5904 | -0.5904 | 0.3798 | 1.24 | 0.1564 | 3.36 | 17.83 | 91,019.23 | -24.35 | -32.92 | -33.77 | -46.36 | 48.76 | 53.15 | -155.67 | -418.87 | 3.38 | -38.19 | 0.2598 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Predilife SA | 317.79k | -4.22m | 21.49m | 19.00 | -- | -- | -- | 67.62 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Nfl Biosciences SAS | 0.00 | -3.48m | 21.64m | 3.00 | -- | 5.44 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
| Poxel SA | 1.55m | -44.24m | 28.49m | 30.00 | -- | -- | -- | 18.43 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
| Gensight Biologics SA | 1.27m | -26.22m | 33.37m | 16.00 | -- | -- | -- | 26.34 | -0.5427 | -0.5427 | 0.0269 | -0.4726 | 0.0723 | -- | 2,534.00 | 79,187.50 | -149.52 | -79.44 | -- | -144.54 | -- | -- | -2,069.53 | -1,036.27 | -- | -- | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Fermentalg SA | 4.06m | -14.15m | 36.49m | 62.00 | -- | 0.702 | -- | 8.99 | -0.3176 | -0.3176 | 0.0917 | 0.6033 | 0.0753 | 0.533 | 3.35 | 65,451.61 | -24.63 | -21.94 | -26.79 | -24.71 | 13.21 | 14.73 | -327.08 | -248.95 | 3.53 | -60.94 | 0.3323 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
| genOway SA | 20.05m | 1.57m | 36.63m | 133.00 | 22.17 | 2.11 | 9.13 | 1.83 | 0.1782 | 0.1782 | 2.28 | 1.88 | 0.619 | 0.773 | 3.10 | 150,724.70 | 4.84 | 0.2166 | 6.64 | 0.3048 | 95.82 | 94.82 | 7.82 | 0.4177 | 1.95 | 28.11 | 0.3047 | -- | 17.55 | 13.16 | 101.55 | 22.35 | -- | -- |
| Novacyt SA | 9.33m | -29.99m | 41.69m | 222.00 | -- | 0.3276 | -- | 4.47 | -0.4247 | -0.426 | 0.1321 | 1.80 | 0.0528 | 1.33 | 0.2622 | 42,034.99 | -16.96 | 17.69 | -20.71 | 23.82 | 43.21 | 62.82 | -321.40 | 23.87 | 4.98 | -79.02 | 0.0036 | 0.00 | -77.28 | 13.49 | -269.46 | -- | -13.46 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Gestys SAas of 31 May 2024 | 17.00k | 0.04% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 0.00 | 0.00% |
| Equigest SAas of 28 Jun 2024 | 0.00 | 0.00% |
| Claresco Finance SAas of 30 Jun 2023 | 0.00 | 0.00% |
